tbuckley/cabot-search huggingface dataset:
Use of Medications for Treating Anxiety and Depression in Cancer Survivors in the United States
Authors: Nikki A. Hawkins, Ashwini Soman, Natasha Buchanan Lunsford, Steven Leadbetter, Juan L. Rodriguez
Journal: Journal of Clinical Oncology (2017)

Purpose This study used population-based data to estimate the percentage of cancer survivors in the United States reporting current medication use for anxiety and depression and to characterize the survivors taking this type of medication. Rates of medication use in cancer survivors were compared with rates in the general population. Methods We analyzed data from the National Health Interview Survey, years 2010 to 2013, identifying cancer survivors (n = 3,184) and adults with no history of cancer (n = 44,997) who completed both the Sample Adult Core Questionnaire and the Adult Functioning and Disability Supplement. Results Compared with adults with no history of cancer, cancer survivors were significantly more likely to report taking medication for anxiety (16.8% v 8.6%, P < .001), depression (14.1% v 7.8%, P < .001), and one or both of these conditions combined (19.1% v 10.4%, P < .001), indicating that an estimated 2.5 million cancer survivors were taking medication for anxiety or depression in the United States at that time. Survivor characteristics associated with higher rates of medication use for anxiety included being younger than 65 years old, female, and non-Hispanic white, and having public insurance, a usual source of medical care, and multiple chronic health conditions. Survivor characteristics associated with medication use for depression were largely consistent with those for anxiety, with the exceptions that insurance status was not significant, whereas being widowed/divorced/separated was associated with more use. Conclusion Cancer survivors in the United States reported medication use for anxiety and depression at rates nearly two times those reported by the general public, likely a reflection of greater emotional and physical burdens from cancer or its treatment.
INDICACIONES, EFECTIVIDAD Y SEGURIDAD DE LAS PRÓTESIS METÁLICAS RECUBIERTAS EN EL MANEJO DE ESTENOSIS BILIARES DE ORIGEN BENIGNO
Authors: A Díaz Gómez, C Carbonell Blanco, A Clemente Sánchez, L Dieguez Montes, L Pérez Carazo, M López Ibáñez, J García Lledó, B Merino Rodríguez, Ó Nogales Rincón, C González-Asanza
Journal: Endoscopy (2016)

Introducción: la CPRE es la técnica de elección en el tratamiento de estenosis biliares benignas (EBB), siendo progresivamente más frecuente el uso de prótesis biliares metálicas recubiertas (PBMR), dado su mayor diámetro respecto a prótesis plásticas y el teórico menor número de intervenciones necesarias para resolver la estenosis.
Brief Report: Risk of Gastrointestinal Perforation Among Rheumatoid Arthritis Patients Receiving Tofacitinib, Tocilizumab, or Other Biologic Treatments
Authors: Fenglong Xie, Huifeng Yun, Sasha Bernatsky, Jeffrey R. Curtis
Journal: Arthritis & Rheumatology (2016)

To evaluate gastrointestinal (GI) perforation in rheumatoid arthritis (RA) patients receiving tofacitinib, tocilizumab, or other biologic agents.
Adjuvant chemotherapy for high-risk upper tract urothelial carcinoma: Results from the Upper Tract Urothelial Carcinoma Collaboration
Authors: N. Hellenthal, S. F. Shariat, V. Margulis, P. I. Karakiewicz, M. Roscigno, C. Bolenz, M. Remzi, A. Weizer, R. Zigeuner, T. M. Koppie
Journal: Journal of Clinical Oncology (2009)

5075 Background: There is relatively little literature regarding the use of adjuvant chemotherapy following radical nephroureterectomy in the management of patients with upper tract urothelial carcinoma (UTUC). Our goal was to determine the incidence of receipt of adjuvant chemotherapy in high-risk patients and the ensuing effect on overall- and cancer-specific survival. Methods: Using an international collaborative database, we identified 1390 patients who underwent nephroureterectomy for non-metastatic UTUC between the years of 1992 and 2006. Of these, 542 (39%) patients were classified as high-risk (pT3N0, pT4N0, and/or lymph node positive). These patients were separated into two groups—those who did and did not receive adjuvant chemotherapy—and were stratified by gender, age group, performance status, tumor grade and stage. Cox proportional hazard modeling and Kaplan-Meier analyses were used to determine overall- and cancer-specific survival amongst the cohorts. Results: Of the high-risk patients, 121 (22%) received adjuvant chemotherapy. Adjuvant chemotherapy was more commonly administered in the context of increased tumor grade and stage (p &lt; 0.001). Median survival in the entire cohort was 24 months (range 0–231 months). There was no significant difference in overall- or cancer-specific survival between those who did and did not receive adjuvant chemotherapy; however age, performance status, tumor grade, and tumor stage were significant predictors of both overall and cancer-specific survival. Conclusions: Adjuvant chemotherapy is infrequently utilized in the treatment of patients with high-risk UTUC after nephroureterectomy. Despite this, it appears that adjuvant chemotherapy confers minimal impact on overall- or cancer-specific survival in this group. No significant financial relationships to disclose.
TCT-597 Why does thin-cap fibroatheroma cluster in the proximal segment in left anterior coronary artery, but are evenly distributed throughout the entire right coronary artery? Results from computational fluid dynamics simulation by CT-FFR
Authors: Takayoshi Toba, Gilwoo Choi, Kenzo Uzu, Toshiro Shinke, Bon-Kwon Koo, Charles Taylor, Hiromasa Otake
Journal: Journal of the American College of Cardiology (2016)
The Roles of Immunity in the Prevention and Evolution of Pulmonary Arterial Hypertension
Authors: Mark R. Nicolls, Norbert F. Voelkel
Journal: American Journal of Respiratory and Critical Care Medicine (2016)

This Perspective provides an in depth overview of the many aspects of inflammation which are associated with many forms of severe pulmonary hypertension.Details of the pathobiology of severe pulmonary hypertension are discussed in the context of the multicellular inflammatory vascular infiltrates which represent a lung vessel response to injury and and a localized immune response.The important question whether inflammation is cause or consequence of pulmonary hypertension should not distract from designing and conducting clinical pilot studies which examine the efficacy of existing immune system modulating drugs.
Comparison of 2 analytical methods of DCE-MRI in advanced NSCLC patients treated with erlotinib and bevacizumab
Authors: V. E. M. van den Boogaart, W. Backes, A. J. De langen, P. Leffers, Hendricus Groen, J. T. Marcus, P. Kappert, E. F. Smit, A. C. Dingemans
Journal: Journal of Thoracic Oncology (2009)
Effectiveness and possible molecular factors predictive of clinical outcomes in patients with transitional cell carcinoma of the urothelial tract (TCCU) treated with VInfluninE: a multicenter retrospective study (MOVIE) of the Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC)
Authors: M. Donini, R. Passalacqua, R. Montironi, S. Lazzarelli, B. Perrucci, F. Nole', G.L. Ceresoli, S. Pignata, F. Torriccelli, G. Tonini, L. Doni, A. Bernardo, B. Marcomini, A. Necchi, E. Betri, U. Degiorgi, R. Sabbatini, E. Rondini, E. Maiello, C. Caminiti
Journal: Annals of Oncology (2015)
Jill Cook
Authors: Johann Windt
Journal: British Journal of Sports Medicine (2016)

Try to develop confidence in yourself before you are 50!

Research that helps clinicians better manage tendinopathy—research that is edgy and novel rather than easy and mundane.

I have a couple—for absolute productivity, ability to contribute to many areas of research, clinical practice and research dissemination. They know who they are.

Treat everyone equally and respectfully unless they give you a good reason not to.

Continuing to consult clinically in the area I research. Doing so has kept me grounded (outliers exist) and fuelled future research.

Have a go, take a risk and take every opportunity presented to you. You do not know where it will lead you.

Anything and everything that I can manage on ageing limbs. I have recently taken up Latin dancing that is challenging …
Severe Pulmonary Vein Stenosis Resulting From Ablation for Atrial Fibrillation
Authors: Erin A. Fender, R. Jay Widmer, David O. Hodge, George M. Cooper, Kristi H. Monahan, Laurie A. Peterson, David R. Holmes, Douglas L. Packer
Journal: Circulation (2016)

The frequency of pulmonary vein stenosis (PVS) after ablation for atrial fibrillation has decreased, but it remains a highly morbid condition. Although treatment strategies including pulmonary vein dilation and stenting have been described, the long-term impacts of these interventions are unknown. We evaluated the presentation of severe PVS, and examined the risk for restenosis after intervention using either balloon angioplasty (BA) alone or BA with stenting. This was a prospective, observational study of 124 patients with severe PVS evaluated between 2000 and 2014. All 124 patients were identified as having severe PVS by computed tomography in 219 veins. One hundred two patients (82%) were symptomatic at diagnosis. The most common symptoms were dyspnea (67%), cough (45%), fatigue (45%), and decreased exercise tolerance (45%). Twenty-seven percent of patients experienced hemoptysis. Ninety-two veins were treated with BA, 86 were treated with stenting, and 41 veins were not treated. A 94% acute procedural success rate was observed and did not differ by initial management. Major procedural complications occurred in 4 of the 113 patients (3.5%) who underwent invasive assessment, and minor complications occurred in 15 patients (13.3%). Overall, 42% of veins developed restenosis including 27% of veins (n=23) treated with stenting and 57% of veins (n=52) treated with BA. The 3-year overall rate of restenosis was 37%, with 49% of BA-treated veins and 25% of stented veins developing restenosis (hazard ratio, 2.77; 95% confidence interval, 1.72-4.45; P<0.001). After adjustment for age, CHA2DS2-VASc score, hypertension, and the time period of the study, there was still a significant difference in the risk of restenosis for BA versus stenting (hazard ratio, 2.46; 95% confidence interval, 1.47-4.12; P<0.001). The diagnosis of PVS is challenging because of nonspecific symptoms and the need for dedicated pulmonary vein imaging. There is no difference in acute success by type of initial intervention; however, stenting significantly reduces the risk of subsequent pulmonary vein restenosis in comparison with BA.
Differential expression of biomarkers in gastrointestinal versus pulmonary carcinoid tumors.
Authors: Erika Fong, Gilbert Peterson, Gargi D. Basu, Richard Blevins, Raheela Ashfaq
Journal: Journal of Clinical Oncology (2012)

e13571 Background: Carcinoid tumors are endocrine neoplasms that commonly arise in the GI and pulmonary system. About 12,000 cases of carcinoid tumor are diagnosed a year with a 5-year survival rate of 67.2% .The majority of the cases present with advance disease with limited treatment options,therefore evaluation of predictive markers for chemotherapeutic agents is highly desirable. We studied the biomarker expression in carcinoid tumors and evaluated any differences based on site of origin. Methods: By computer search we retrospectively identified all cases submitted to Caris Life Sciences with the diagnosis of “carcinoid”. The cases were classified by primary site into three groups: Pulmonary, GI tract (including esophagus, stomach, small bowel, colon, rectum, appendix and pancreas) and miscellaneous. Biomarker expression performed by IHC and scored semi quantitatively by a pathologist for SPARC mono, SPARC poly, Her2, TOPO2, TOPO1, PGP, MRP1, PTEN, TS, ERCC1, RRM1,MGMT, C-KIT, ER, PR and AR and SSTR2 and SSTR5 analysis by DNA Microarray were compared between the groups. Results: 146 carcinoid tumors were interrogated for biomarkers, 33 pulmonary, 97 GI and 16 miscellaneous (mediastinum, thymus, cervix, breast and unknown primary site). Due to small number of tumors in the miscellaneous category, analysis was restricted to pulmonary and GI carcinoid tumors only. Based on our analysis the pulmonary carcinoids differentially express Topo2, PGP, MGMT, CKIT and PR, while the GI carcinoids differentially express Topo1, RRM1 and ER and SSTR2 and SSTR5. There is equivalent expression of SPARC, MRP1, PTEN, TS, ERCC1 at both sites . All pulmonary and GI carcinoid tumors were negative for Her2. Conclusions: Based on this study it appears that there are differences in biomarker expression in GI and Pulmonary Carcinoid tumors. Treatment with irinotecan, gemcitabine, anti-estrogens and Octreotide may be more relevant in GI carcinoids based on molecular markers present while targets associated with response to anthracyclines, temozolomide, imatinib may be more commonly expressed in pulmonary carcinoid tumors. Further studies are needed to understand the underlying biology and molecular drivers in this group of tumors.
TCT-736 Accuracy of Predicted Orthogonal Projection Angles for Valve Deployment during Transcatheter Aortic valve implantation
Authors: Arie Steinvil, Gaby Weissman, Guy Weigold, Andrew Ertel, Smita I. Negi, Sang Yeub Lee, Christian Shults, Rebecca Torguson, Petros Okubagzi, Augusto Pichard, Lowell Satler, Itshac Itsik Ben-dor, Toby Rogers, Sarkis Kiramijyan, Edward Koifman, Ron Waksman
Journal: Journal of the American College of Cardiology (2016)
Clinical and Prognostic Significance of Bone Marrow Imaging of Appendicular Skeletons By Low-Dose Multi-Detector Computed Tomography in Patients with Aplastic Anemia and Myelodysplastic Syndorme
Authors: Manabu Fujisawa, Tomotaka Ugai, Yasuhito Suehara, Keisuke Seike, Kota Fukumoto, Masafumi Fukaya, Hiroki Sugihara, Masami Takeuchi, Kosei Matsue
Journal: Blood (2014)
Curcumin suppresses growth of head and neck squamous cell carcinoma
Authors: Maria M. Lotempio, Helen Steele, Barthi Ramamurthy, Veena Mysore, Rita Chakrabarti, Thomas C. Calcaterra, Eri Srivatsan, Marilene B. Wang
Journal: Cancer Research (2004)

Proc Amer Assoc Cancer Res, Volume 45, 2004

1520 

The purpose of this study was to determine whether curcumin would trigger cell death in the head and neck squamous cell carcinoma (HNSCC) cell lines CCL 23 and CAL 27 in a dose-dependent fashion, both in vitro and in vivo . In vitro studies included MTT assay of the HNSCC cells after treatment with curcumin. Control cells were treated with dimethylsulfoxide (DMSO) or saline. CCL23 and CAL27 were plated into 96-well plates, serum starved for 24 hours to synchronize cell cycles, treated with curcumin or DMSO for eight hours, and allowed to incubate in regular growth media for 8 and 15 hours after treatment before analysis of cell viability. MTT results showed that at both eight and fifteen hours after treatment, CCL23 cell lines had the greatest reduction in cell viability at concentrations between 100-300uM, with nearly 100% cell survival at 100uM and less than 5% survival at 300uM. CAL27 cell lines showed an even greater sensitivity to curcumin treatment. Reduction of CAL27 cell viability began at 60uM, and 0% survived at concentrations of 300uM. Fifteen hours after treatment with 100 μM of curcumin, CAL27 cell lines showed continued cell death, with an 83% reduction in cell viability. In vivo studies were done on HNSCC xenograft tumors grown in female nude mice. Curcumin paste was applied topically to each mouse tumor on a daily basis for 4 weeks. Tumors were measured in 3 dimensions each week and growth curves plotted. Blood and organs were harvested from the mice for toxicity studies after completion of the experiment. The xenograft tumors exhibited more than 50% decrease in size with the curcumin/saline paste. Curcumin/DMSO paste had only a modest suppressive effect on tumor growth, while control tumors continued to grow rapidly. In conclusion, curcumin has a direct effect on CCL23 and CAL27, reducing viability in both cell lines in a dose-dependent fashion. Both cell lines showed continued cell death over a period of several hours, suggesting that curcumin triggers the apoptotic pathway in these head and neck cancer cell lines rather than producing a sudden cell necrosis. In addition, curcumin/saline paste had a significant suppressive effect on HNSCC xenograft tumors in female nude mice, confirming curcumin’s antitumor properties in vivo .
CD19-Redirected Chimeric Antigen Receptor T (CART19) Cells Induce a Cytokine Release Syndrome (CRS) and Induction of Treatable Macrophage Activation Syndrome (MAS) That Can Be Managed by the IL-6 Antagonist Tocilizumab (toc).
Authors: Stephan A. Grupp, David L Porter, David T Teachey, David M. Barrett, Anne Chew, Erica Suppa, Bruce L. Levine, Michael Kalos, Carl H. June
Journal: Blood (2012)
Microcephaly Proteins Wdr62 and Aspm Define a Mother Centriole Complex Regulating Centriole Biogenesis, Apical Complex, and Cell Fate
Authors: Divya Jayaraman, Andrew Kodani, Dilenny M. Gonzalez, Joseph D. Mancias, Ganeshwaran H. Mochida, Cristiana Vagnoni, Jeffrey Johnson, Nevan Krogan, J. Wade Harper, Jeremy F. Reiter, Timothy W. Yu, Byoung-il Bae, Christopher A. Walsh
Journal: Neuron (2016)
Burden of bloodstream infections among ambulatory pediatric hematology/oncology patients with a central line.
Authors: Constance Barysauskas, David G. Bundy, Aditya H. Gaur, Jeffrey D. Hord, Marlene R. Miller, Eric J. Werner, Cindi Winkle, Amy Billett
Journal: Journal of Clinical Oncology (2016)

262 Background: Pediatric hematology/oncology (PHO) patients are at high risk of bloodstream infections (BSI). The burden of BSI in PHO patients in the ambulatory setting has not been well documented. Methods: The Children’s Hospital Association leads the Childhood Cancer and Blood Disorders Network, a multicenter United States quality improvement collaborative, working to reduce the incidence of inpatient and ambulatory Central Line-Associated BSI (CLABSI) among PHO patients. Positive blood culture events (+BCE) were adjudicated as CLABSI, single positive blood cultures (SPBC) with potential commensals, or secondary BSI (attributed to source other than the central line) following standardized National Healthcare Safety Network definitions. Our study investigated the prevalence of +BCE among all centers with 90% complete monthly reporting of both +BCE and central line days (CLD) for at least one year (n=25) between January 2012 and September 2014. Ambulatory and inpatient BSI rates and 95% confidence intervals (CI) were calculated as the number of +BCE per 1,000 CLD per month. Results: A total of 1,747 +BCE and 4,883,413 CLD were reported among our target ambulatory population, whereas 1,095 +BCE and 353,259 CLD were reported among our corresponding inpatient population [Table]. While the CLABSI and SPBC rates were significantly lower in the ambulatory setting compared to inpatient (p&lt;0.001), the total number of ambulatory CLABSI and SPBC events was 2.0 and 1.6 times higher than inpatient events, respectively. Conclusions: Our findings from a large multicenter collaborative demonstrate the burden of BSI among ambulatory PHO patients and identify benchmarks for future quality improvement work.Further investigation is necessary to develop effective infection reduction strategies for ambulatory PHO patients with central lines. [Table: see text]
Up-Front Thalidomide-Dexamethasone (THAL) and Double Autologous Transplantation (Double TX) for Multiple Myeloma: Comparison with Double TX without Added Thalidomide and Prognostic Implications of Chromosome 13 Deletion and Translocation t(4;14).
Authors: Michele Cavo, Nicoletta Testoni, Carolina Terragna, Elena Zamagni, Paola Tacchetti, Chiara Nicci, Matteo Renzulli, Elena Montanari, Giulia Perrone, Delia Cangini, Tiziana Grafone, Michela Ceccolini, AnnaMaria Brioli, Giovanni Martinelli, Patrizia Tosi, Michele Baccarani
Journal: Blood (2006)
INCIDENCIA DE COMPLICACIONES EN LA COLONOSCOPIA. HAY QUE CAMBIAR LAS REFERENCIAS?
Authors: J De La Peña, M Arias, MJ Lopez Arias, C Rodriguez De Lope, A Teran, S Llerena, P Fernandez Gil, MJ Gaarcia Garcia, S Alvarez, P Ruiz Bueno
Journal: Endoscopy (2016)

Introducción: la incidencia de complicaciones de la colonoscopia esta establecida desde hace varias decadas. La exigencia de la colonoscopia de calidad pueden incidir en la frecuencia de complicaciones.
Robustness of Reconstructed Ancestral Protein Functions to Statistical Uncertainty
Authors: Geeta N. Eick, Jamie T. Bridgham, Douglas P. Anderson, Michael J. Harms, Joseph W. Thornton
Journal: Molecular Biology and Evolution (2016)

Hypotheses about the functions of ancient proteins and the effects of historical mutations on them are often tested using ancestral protein reconstruction (APR)-phylogenetic inference of ancestral sequences followed by synthesis and experimental characterization. Usually, some sequence sites are ambiguously reconstructed, with two or more statistically plausible states. The extent to which the inferred functions and mutational effects are robust to uncertainty about the ancestral sequence has not been studied systematically. To address this issue, we reconstructed ancestral proteins in three domain families that have different functions, architectures, and degrees of uncertainty; we then experimentally characterized the functional robustness of these proteins when uncertainty was incorporated using several approaches, including sampling amino acid states from the posterior distribution at each site and incorporating the alternative amino acid state at every ambiguous site in the sequence into a single "worst plausible case" protein. In every case, qualitative conclusions about the ancestral proteins' functions and the effects of key historical mutations were robust to sequence uncertainty, with similar functions observed even when scores of alternate amino acids were incorporated. There was some variation in quantitative descriptors of function among plausible sequences, suggesting that experimentally characterizing robustness is particularly important when quantitative estimates of ancient biochemical parameters are desired. The worst plausible case method appears to provide an efficient strategy for characterizing the functional robustness of ancestral proteins to large amounts of sequence uncertainty. Sampling from the posterior distribution sometimes produced artifactually nonfunctional proteins for sequences reconstructed with substantial ambiguity.